



**PRESS RELEASE**

**NEOPHARMED GENTILI S.P.A. – CREATION OF FIRST RANKING PLEDGE OVER THE SHARE CAPITAL OF NEOPHARMED S.P.A. AND VALEAS S.P.A.**

*Milan, May [16], 2024* - Neopharmed Gentili S.p.A., a joint stock company (*società per azioni*) incorporated under the laws of Italy (the “**Issuer**” or “**Neopharmed**”) and its holding company Neon MidCo S.p.A. (“**MidCo**”) have obtained on April 18, 2024 the clearance from the Presidency of the Italian Council of Ministers’ under the applicable Italian legislation on Golden Power with respect to the creation of first ranking pledge over, respectively: (i) the shares of the Issuer held by MidCo representing 100% of the share capital of the Issuer (the “**Issuer Pledge**”) and (ii) the shares of Valeas S.p.A. (**Valeas**) held by the Issuer representing 100% of the share capital of Valeas (the “**Valeas Pledge**” and, together with the Issuer Pledge, the “**Post-Clearance Share Pledges**”).

On May 15, 2024, MidCo and the Issuer have, respectively, entered into two pledge agreements pursuant to which the Issuer Pledge and the Valeas Pledge have been created.

As a result, the €350,000,000 7.125% Senior Secured Fixed Rate Notes due 2030 and the €400,000,000 Senior Secured Floating Rate Notes due 2030 issued by the Issuer on April 8, 2024, as well as the €130,000,000 super senior revolving credit facility made available under a super senior revolving credit facility agreement dated March 22, 2024 by and between, among others, the Issuer and the lenders named therein, are now secured also by the Post-Clearance Share Pledges.

\*\*\*

**For further information:**  
Neopharmed Gentili S.p.A.

*Investor Relations*  
[investors@neogen.it](mailto:investors@neogen.it)

\*\*\*

**Neopharmed Gentili S.p.A.**

*Neopharmed Gentili is a pharmaceutical company founded in Italy with historic roots in its territory, which is rapidly expanding beyond national borders thanks to a consolidated and reliable experience in M&A and Licensing transactions, especially with multinational partners. Research, responsibility, and care are the pillars that guide Neopharmed Gentili's mission to improve the health and quality of life of patients, caregivers, and healthcare personnel. Neopharmed Gentili's ambition is to help people live long and healthy lives, acting with ethical value and scientific precision, and offering solutions with high therapeutic value.*

[www.neogen.it](http://www.neogen.it)

\*\*\*

*This press release is for information purposes only and does not constitute any offer to sell or the solicitation of an offer to buy any security in the United States or in any other jurisdiction. The Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or applicable state or foreign securities laws and may not be offered or sold in the United States without registration under federal or applicable state securities laws or an applicable exemption from such registration requirements.*

*This press release does not constitute an offer to the public in Italy of financial products, as defined under Article 1, paragraph 1, letter (t) of legislative decree of February 24, 1998, no. 58, as amended (the "Italian Financial Act"). The Notes cannot be offered, sold or delivered, directly or indirectly, in Italy either on the primary or on the secondary market to any natural persons nor to entities other than qualified investors (investitori qualificati) as referred to in Article 2, paragraph (e), of the Prospectus Regulation or unless in any circumstances which are exempt from the rules on public offerings pursuant to Article 1 of the Prospectus Regulation and the implementing regulations issued by the Commissione Nazionale per le Società e la Borsa, the Italian securities and financial markets regulator ("CONSOB"), including CONSOB Regulation No. 20307 of February 15, 2018, as amended, Article 34-ter, paragraph 1, letter (b) of CONSOB Regulation no. 11971 of May 14, 1999, as amended (the "Issuers Regulation") implementing Article 100 of the Italian Financial Act, and the applicable Italian laws and regulations.*

*This press release is for informational purposes only and does not constitute and shall not, in any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of the Prospectus Regulation. The Offering will be made pursuant to an exemption under the UK Prospectus Regulation and the Prospectus Regulation, as implemented in Member States of the European Economic Area, from the requirement to produce a prospectus for offers of securities.*

*This press release is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are "investment professionals" falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This press release is directed only at Relevant Persons and must not be acted on or relied upon by persons who are not*

*Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.*

*Manufacturer target market (MIFID II product governance; UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail investors in EEA or the United Kingdom, respectively.*